Composition containing fistular onion stalk and oat extracts and used for promoting height growth of children and teenagers and preparation method of composition

A composition of welsh onion root and oat extracts addresses the limitations of existing height-enhancement methods by synergistically increasing growth hormone secretion and bone growth markers, effectively enhancing bone density and length in children and adolescents.

CN119072324APending Publication Date: 2024-12-03WELLREST CO LTD
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202480001441.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-03-31
Filing Date
2024-03-27
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Existing methods for increasing height, such as growth hormone therapy and Ilizarov surgery, are costly, risky, or lack scientific verification, and there is a need for a safe and effective natural alternative to enhance bone density and length.

Method used

A composition containing welsh onion root and oat extracts, extracted at specific temperatures and ratios, synergistically increases growth hormone secretion and enhances bone growth indicators like osteocalcin and bone-specific alkaline phosphatase activity.

Benefits of technology

The composition effectively increases bone density and length in growing children and adolescents by enhancing growth hormone secretion and bone growth markers, offering a safe and scientifically verified natural alternative.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119072324A_ABST
    Figure CN119072324A_ABST
Patent Text Reader

Abstract

The present invention relates to a composition for increasing bone mineral density and / or bone length comprising fistular onion stalk and oat extracts as active ingredients, and more specifically, to a composition comprising fistular onion stalk and oat extracts as active ingredients, according to the present invention, it has been confirmed that it increases bone mineral density and bone length by increasing secretion of growth hormone and increasing a plurality of indicators involved in bone growth (osteocalcin (OPG) and bone-specific alkaline phosphatase activity), and thus it is expected to be effective in bone mineral density increase and / or bone length increase in adult children or adolescents.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a composition for increasing bone density and / or increasing bone length, which comprises welsh onion root and oat extracts as effective ingredients. Background Art

[0002] In recent years, due to the westernization of body shape and the rise of average height, the attention to height growth factor is increasing. If growth is defined as a broad concept, it not only includes the increase of height, but also includes the increase of the size and function of various organs of the body, but if growth is defined as a narrow concept, it can only mean the increase of height. This increase in height is achieved through bone metabolism, which includes the synthesis of cartilage tissue caused by various factors (nutrition and growth hormone, etc.), the growth of bone length and the extensive proliferation of bone tissue. Bone (bone) tissue is a special differentiated connective tissue, which is a connective tissue composed of various cells such as mesenchymal cells, chondrocytes, osteoblasts, osteoclasts and bone marrow cells. The bone resorption amount of osteoclasts is balanced with the bone formation amount of osteoblasts, and the bone formation ability of osteoblasts in the growth period reaches the highest level, and the bone formation amount far exceeds the bone resorption amount, thus realizing bone growth.

[0003] Bone growth is achieved through the interaction between osteoclasts and osteoblasts. If the bone is absorbed by osteoclasts, osteoblasts can reassemble calcium and phosphorus to achieve bone growth. When the activity of osteoblasts is higher than that of osteoclasts, bone growth can occur. Conversely, bone destruction can occur, leading to osteoporosis. The situation in which the activity of osteoblasts becomes higher than that of osteoclasts is mainly in the growing children or adolescents (growth hormone secretion period).

[0004] On the other hand, hormones that affect growth include insulin, thyroid hormones, sex hormones, etc. Among them, growth hormone, as a hormone secreted by the anterior pituitary gland, performs the functions of making the body grow, promoting bone calcification, increasing protein synthesis, and promoting immunity. Since the energy source available to the brain, which is the main driving force for growth, is glucose, growth hormone is related to blood sugar. When growth hormone is secreted excessively, the sugar concentration in the blood continues to rise, which can induce diabetes.

[0005] Other methods of growing taller include administration of growth hormone preparations, Ilizarov surgery, and taking health foods. However, growth hormone therapy is too long and expensive, and has been found to induce cancer and interfere with other growth factors. Ilizarov surgery is a surgery that cuts and lengthens the leg bones. It is difficult for ordinary people to use it in terms of the pain and cost of the patient, and most health foods used to promote growth have not been scientifically verified.

[0006] The Korean Patent Gazette (Grant No. 10-2070312) describes a composition containing scallion extract as an effective ingredient and a preparation method thereof, but the present invention has the following differences: the present invention synergistically increases the secretion of growth hormone through scallion and oat extracts. In addition, the present invention confirms the effect of increasing bone density and / or increasing bone length by increasing multiple indicators involved in bone growth (osteocalcin (OPG) and bone-specific alkaline phosphatase activity).

[0007] Thus, the present inventors developed a composition for increasing bone density and / or increasing bone length, which contains welsh onion root and oats extracts as active ingredients, thereby completing the present invention. Summary of the invention

[0008] Problem that the invention aims to solve

[0009] The present invention aims to provide a composition for increasing bone density and / or increasing bone length, which comprises welsh onion root and oat extracts as active ingredients.

[0010] Means used to solve problems

[0011] The invention relates to a pharmaceutical composition for increasing bone density and / or increasing bone length, which comprises scallion white and oat extract as effective ingredients.

[0012] In addition, the present invention relates to a pharmaceutical composition for increasing bone density and / or increasing bone length, characterized in that the scallion and oat extracts are extracts based on any solvent selected from the group consisting of water, alcohols having 1 to 4 carbon atoms and mixtures thereof.

[0013] In addition, the present invention relates to a pharmaceutical composition for increasing bone density and / or increasing bone length, characterized in that the scallion and oat extracts are hot water extracts extracted at a temperature of 70° C. to 90° C. for 4 to 8 hours.

[0014] In addition, the present invention relates to a pharmaceutical composition for increasing bone density and / or increasing bone length, characterized in that the scallion white and oat extracts are extracts obtained by mixing scallion white extracts and oat extracts at a weight ratio of 1:8 to 12, respectively. Preferably, the scallion white and oat extracts are extracts mixed at a weight ratio of 1:8 to 12, and more preferably, the scallion white and oat extracts are extracts mixed at a weight ratio of 1:8 to 12, and more preferably, the extracts mixed at a weight ratio of 1:10 show a synergistic effect of increasing bone density and / or increasing bone length.

[0015] If the scallion white and oat extracts are out of the range of extracts mixed in a weight ratio of 1:8 to 12, the synergistic effect of increasing bone density and / or increasing bone length will be reduced.

[0016] In addition, the present invention relates to a pharmaceutical composition for increasing bone density and / or increasing bone length, characterized in that the pharmaceutical composition for increasing bone density and / or increasing bone length is used to increase bone density and / or increase bone length in growing children or adolescents.

[0017] The invention relates to a health functional food composition for increasing bone density and / or increasing bone length, which comprises scallion white and oat extract as effective ingredients.

[0018] In addition, the present invention relates to a health functional food composition for increasing bone density and / or increasing bone length, characterized in that the scallion white and oat extracts are extracts based on any solvent selected from the group consisting of water, alcohols with 1 to 4 carbon atoms and mixtures thereof.

[0019] In addition, the present invention relates to a health functional food composition for increasing bone density and / or increasing bone length, characterized in that the scallion and oat extracts are hot water extracts extracted at a temperature of 70° C. to 90° C. for 4 to 8 hours.

[0020] In addition, the present invention relates to a health functional food composition for increasing bone density and / or increasing bone length, characterized in that the scallion white and oat extracts are extracts obtained by mixing scallion white extracts and oat extracts at a weight ratio of 1:8 to 12, respectively. Preferably, the scallion white and oat extracts are extracts mixed at a weight ratio of 1:8 to 12, and more preferably, are extracts mixed at a weight ratio of 1:10.

[0021] In addition, the present invention relates to a health functional food composition for increasing bone density and / or increasing bone length, characterized in that the health functional food composition for increasing bone density and / or increasing bone length is used to increase the bone density or bone length of growing children or adolescents.

[0022] The present invention relates to a method for preparing a pharmaceutical composition for increasing bone density and / or increasing bone length, the method comprising the following steps: extracting and mixing scallion white and oat respectively by any solvent selected from the group consisting of water, alcohols with 1 to 4 carbon atoms and mixtures thereof, so as to prepare scallion white and oat extracts.

[0023] In addition, the present invention relates to a method for preparing a health functional food composition for increasing bone density and / or increasing bone length, the preparation method comprising the following steps: extracting and mixing scallion white and oat respectively by any solvent selected from the group consisting of water, alcohols with 1 to 4 carbon atoms and mixtures thereof to prepare scallion white and oat extracts.

[0024] Relative to the total weight of the entire pharmaceutical composition, preferably, 0.001 wt% to 50 wt% is added, more preferably, 0.001 wt% to 40 wt% is added, and most preferably, 0.001 wt% to 30 wt% of the scallion and oat extracts are added.

[0025] The pharmaceutical composition can be prepared into the form of oral dosage form (such as powder, granule, tablet, capsule, suspension, emulsion, syrup, liquid, aerosol, etc.), external agent, suppository and sterile injection according to conventional method respectively and use. As the carrier, excipient and diluent that can be included in the pharmaceutical composition, lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum arabic, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talcum powder, magnesium stearate and mineral oil can be included. When formulation, diluent or excipient (commonly used filler, extender, bonding agent, wetting agent, disintegrating agent, surfactant, sweetener and sour agent, etc.) are used to prepare. Solid preparations for oral administration include tablets, pills, powders, granules and capsules, etc., which are prepared by mixing at least one excipient (e.g., starch, calcium carbonate, sucrose or lactose and gelatin, etc.) in the solubilized decursinol of the present invention. In addition, lubricants such as magnesium stearate and talcum powder can also be used in addition to simple excipients. Liquid preparations for oral administration include suspensions, oral solutions, emulsions and syrups, etc., which, in addition to water and liquid paraffin as commonly used simple diluents, can also include a variety of excipients (e.g., wetting agents, sweeteners, aromatics, preservatives and acidulants). Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations and suppositories. Propylene glycol, polyethylene glycol, vegetable oils (e.g., olive oil) and injectable esters (e.g., ethyl oleate) can be used as non-aqueous solvents and suspensions. As the base of the suppository, synthetic fatty acid ester (witepsol), polyethylene glycol, Tween-61, cocoa butter, laurel oil, glycerin gelatin, etc. can be used.

[0026] The dosage of the pharmaceutical composition of the present invention can be changed according to the age, sex and body weight of the subject to be treated, the severity of the specific disease to be treated or pathological condition, the disease or pathological condition, the route of administration and the judgement of the prescriber. The dosage based on these factors is determined within the level of ordinary technicians in the field, and usually the dosage is in the range of 1mg / kg / day to about 5000mg / kg / day. Administration can be administered once a day, or it can be administered multiple times. The dosage does not limit the scope of the present invention in any way.

[0027] The pharmaceutical composition of the present invention can be administered to mammals (mice, livestock and humans, etc.) through various routes. All modes of administration are foreseeable, for example, administration can be performed by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or intracerebral injection and skin application. The scallion white and oat extract of the present invention has almost no toxicity and side effects, so it is a drug that can be used safely even if it is taken for a long time for the purpose of prevention.

[0028] The health functional food composition of the present invention is formulated in the same manner as the pharmaceutical composition, and can be used as a functional food or added to various foods. For example, the foods to which the health functional food composition can be added may include beverages, alcoholic beverages, biscuits, diet bars, dairy products, meat, chocolate, pizza, ramen, other noodles, chewing gum, ice cream, vitamin complexes, health supplements, etc.

[0029] The health functional food composition of the present invention may not only include scallion white and oat extract as effective ingredients, but may also include ingredients commonly added during food production, such as protein, carbohydrates, fat, nutrients, seasonings and flavoring agents. As examples of the above-mentioned carbohydrates, monosaccharides (e.g., glucose, fructose, etc.), disaccharides (e.g., maltose, sucrose, oligosaccharides, etc.) and polysaccharides (e.g., common sugars (such as dextrin, cyclodextrin, etc.) and sugar alcohols (such as xylitol, sorbitol, erythritol, etc.) may be included. As flavoring agents, natural flavoring agents [thaumatin, stevia extract (e.g., sabaudioside A, glycyrrhizin, etc.)] and synthetic flavoring agents (saccharin, aspartame, etc.) may be used. For example, when the food composition of the present invention is prepared into energy drinks and beverages, citric acid, liquid fructose, white sugar, glucose, acetic acid, malic acid, fruit juice and various plant extracts, etc. may be additionally included.

[0030] The health functional food composition may include tablets, capsules, pills or liquids, and the food to which the extract of the present invention can be added may include, for example, various foods, beverages, chewing gum, tea, vitamin complexes and health functional foods. When these are taken, it means that a specific effect is produced on health, but unlike ordinary medicines, the advantage is that since food is used as a raw material, there are no side effects that may occur when taking medicines for a long time. The health functional food of the present invention obtained in this way is very useful because it can be taken daily. The amount of scallion white and oat extract added in this health functional food cannot be uniformly specified because it varies according to the type of health functional food as the object, but as long as it is added within the range that does not affect the original taste of the food, it is generally 0.01% to 50% by weight, preferably 0.1% to 20% by weight relative to the object food. In addition, for health functional foods in the form of pills, granules, tablets or capsules, 0.1% to 100% by weight is generally added, preferably 0.5% to 80% by weight. The amount added does not limit the scope of the present invention in any way.

[0031] Effects of the Invention

[0032] The present invention relates to a composition for increasing bone density and / or increasing bone length, which comprises scallion white and oat extract as effective ingredients. More specifically, a composition comprising scallion white and oat extract as effective ingredients has been developed. The inventors have confirmed that the present invention can increase bone density and increase bone length by increasing growth hormone secretion and increasing multiple indicators involved in bone growth (osteocalcin (OPG) and bone-specific alkaline phosphatase activity).

[0033] Therefore, it is expected to be effective in increasing the bone density and / or increasing the bone length in growing children or adolescents. BRIEF DESCRIPTION OF THE DRAWINGS

[0034] Figure 1 The diagram shows the preparation process of the scallion white and oat mixture and the scallion white and barley mixture of the present invention.

[0035] Figure 2 The binding of Fistuloside C to the active sites of GDF5 and IGF-1R is shown.

[0036] Figure 3 The experimental design of the animal experiment of the present invention is shown.

[0037] Figure 4 The lean body mass (LBM) and body fat content after 4 weeks of intervention with the present invention are shown.

[0038] Figure 5 and Figure 6 Shown are changes in serum glucose concentration after administration of 2 g glucose / kg bw in an oral glucose tolerance test (OGTT) of the present invention.

[0039] Figure 7 The graph shows changes in serum glucose concentration after administration of 1 U insulin / kg bw in the intraperitoneal insulin tolerance test (IPITT) of the present invention.

[0040] Figure 8 and Fig. 9 The difference between bone length and bone density (BMD) before and after 4 weeks of intervention with the present invention is shown.

[0041] Figures 10 to 12 The bacterial composition, diversity and metagenome function of cecum feces of the present invention are shown.

[0042] Fig.13 Shown is the cell viability measured by MTT assay after 24 hours of treatment of MG63 cells of the present invention. DETAILED DESCRIPTION

[0043] The preferred embodiments of the present invention are described in detail below. However, the present invention is not limited to the embodiments described herein and may be embodied in other forms. On the contrary, the present invention is provided to make the contents described herein thorough and complete and to fully convey the ideas of the present invention to those skilled in the art.

[0044] [Example 1. Establishment of standard process for extracts of scallion, oats and barley and investigation of index components]

[0045] After washing oats and barley, they were extracted with hot water at 80°C for 6 hours, and filtered with a 25μm filter to obtain oat hot water extract and barley hot water extract. After washing scallion, they were chopped and hot air dried at 50°C, then the hot air dried product was crushed and extracted with hot water at 80°C for 6 hours, filtered with a 25μm filter to obtain scallion hot water extract. The scallion, oat and barley hot water extracts were concentrated under reduced pressure at 65°C, and freeze-dried under -40°C rack, -70°C cold trap and 9mTorr vacuum conditions to obtain respective scallion, oat and barley freeze-dried products. Next, the scallion, oat and barley freeze-dried products were crushed with a 100-mesh high-power grinder (Power Mill), and the crushed products were mixed. The following tests were carried out with the scallion + oat mixture and the scallion + barley mixture. In the following Figure 1The preparation process diagrams of the scallion white, oat mixture and the scallion white, barley mixture are organized and shown.

[0046] The yields of the hot water extracts of scallion white, oats and barley are summarized and shown in Table 1. In addition, the contents of alliin and β-glucan contained in the hot water extracts of scallion white, oats and barley are summarized and shown in Table 2.

[0047] [Table 1]

[0048] distinguish Scallion Extract Oat Extract Barley Extract Yield (%) 2.9 6.1 4.8

[0049] [Table 2]

[0050] Indicator ingredients Shallot Extract Barley Extract Oat Extract Alliin(mg / 100g) 6.57 - - β-Glucan (mg / 100g) - 74.08 86.49

[0051] [Example 2. Detection of the effect of scallion white / oat extract mixture and scallion white / barley extract mixture on height growth]

[0052] 2-1. Experimental Group

[0053] The animal experiment was approved by the Animal Ethics Committee (HSUIACUC-22-052 (1) June 21, 2022). Four-week-old mice were divided into 7 groups, as shown in Table 3 below, with 10 mice allocated to each group.

[0054] [Table 3]

[0055]

[0056]

[0057] 2-2. Index components of scallion and oats

[0058] The dried green onion contained 65.7±0.11 mg alliin / kg and the oat index component 865±0.56 mg β-glucan / kg dried oats (Table 4).

[0059] [Table 4]

[0060] Indicator ingredients Scallion Extract Oat Extract Alliin(mg / 100g) 6.57 - β-Glucan (mg / 100g) - 86.49

[0061] 2-3. In silico simulation of the interaction between ingredients in scallion and oats and GDFS and IGF- The binding energy of lR

[0062] When searching for binding energies with GDF5 and IGF-1R lower than -9 kcal / mol, several ingredients in scallion and oats fall into this category. This suggests that scallion and oats both regulate the functions of GDF5 and IGF-1R. The binding free energies (ΔG; kcal mol) of food compounds with growth differentiation factor 5 (GDF5) and insulin-like growth factor 1 receptor (IGF-1R) determined by free energy changes are summarized in Table 5 below. -1 ), and Figure 2 The binding of Fistuloside C to the active sites of GDF5 and IGF-1R is shown in FIG.

[0063] [Table 5]

[0064]

[0065] 2-4. Experimental Design

[0066] Experimental design Figure 3 As shown. The mixing ratio of the extracts was prepared as scallion water extract: oat water extract = 1:10. First, the reason for selecting the mixing ratio is that it has been confirmed through repeated experiments that the effect is better when scallion and oat extracts are used compared to using scallion extract alone. Secondly, it has been confirmed through repeated experiments that the effect is best when the scallion extract and oat extract are prepared at the mixing ratio compared to other mixing ratios. In addition, during a period of 4 weeks, a fat diet with 38% energy was taken as a dietary method, and the extract was taken orally every day.

[0067] 2-5. Weight gain, dietary efficiency, and tissue weight Experiment result

[0068] After 4 weeks of intervention, the results of body weight gain, food intake and insulin resistance are collated and shown in Table 6 below.

[0069] [Table 6]

[0070]

[0071] During the intervention period, there was no significant difference in weight gain between the groups, and there was no statistical difference in dietary efficiency, but the positive-control and H-GOO groups showed a higher trend. Dietary intake showed an overall increasing trend in scallion and oat extracts, especially, the high-dose scallion oat extract group was higher than the other groups. The visceral fat content (the sum of uterine fat and retroperitoneal fat) in the H-GOO group was lower than that in the control group, while the other groups were similar to the control group. The total leg muscle mass in the control group was the lowest, and from low to high, it was the positive control group, L-GOO, M-GOO, and H-GOO.

[0072] When muscle mass and abdominal fat mass were measured using bone densitometer (DEXA), the control group had the lowest muscle mass in the buttocks and legs, while the positive control group, M-GOO group, and H-GOO group had higher muscle mass than the control group ( Figure 4 A). The control group had the highest abdominal and leg fat mass measured by bone densitometer (DEXA), while the positive control group and H-GOO group had lower abdominal and leg fat mass than the control group ( Figure 4 B).

[0073] 2-6. Results of oral glucose tolerance test

[0074] Since growth hormone, IGF-1, and insulin are involved in prepubertal growth, blood glucose metabolism was examined. Specifically, an oral glucose tolerance test was performed by orally administering 2 g / kg body weight of glucose to fasting mice.

[0075] HOMA-IR, which indicates insulin resistance, was the highest in the control group and the lowest in the H-GOO group. The fasting serum insulin concentrations of the control group and the positive control group were higher than those of the H-GOO group (Table 6 above).

[0076] The fasting blood glucose was the highest in the control group. Compared with the control group, the fasting blood glucose of the positive control group decreased sharply, especially from 50 minutes onwards, and decreased in a dose-dependent manner in GOO. After oral administration of glucose, blood glucose increased from 30 minutes to 40 minutes, and the control group had the highest blood glucose at 50 minutes. The H-GOO group had the lowest peak blood glucose level. When blood glucose decreased after the peak blood glucose level, blood glucose levels in the positive control group and the GOO group decreased compared with the control group. The peak blood glucose level of the H-GOO group at 30 minutes was also lower than that of the other groups, and blood glucose began to decrease from 40 minutes and was lower than that of the positive control group. In conclusion, like the positive control group, the oral glucose tolerance of the M-GOO group and the H-GOO group was improved compared with the control group, and the oral glucose tolerance of the H-GOO group was better than that of the positive control group ( Figure 5 A).

[0077] When the area under the curve of blood glucose changes in an oral glucose tolerance test (OGTT) was plotted, the control group was similar to the positive control group in terms of the area of ​​blood glucose changes from 0 to 40 minutes as the first part, and decreased in a dose-dependent manner in GOO, with H-GOO being the lowest. In the second part from 40 to 120 minutes, the control group was the highest, and the positive control group was lower than the control group, and decreased in a dose-dependent manner in GOO, with H-GOO being the lowest ( Figure 5 B).

[0078] During the oral glucose tolerance test (OGTT), the change in serum insulin concentration was highest at 20 minutes and decreased at 60 minutes in the positive control group, M-GOO, and H-GOO, while it was highest at 60 minutes in the control group and L-GOO. At this time, it was higher in the control group and L-GOO ( Figure 6 C).

[0079] At 0 to 20 minutes as the first part, the area was higher in the positive control group, M-GOO, and H-GOO relative to the control group, and at 20 to 90 minutes as the second part, the area was highest in the control group and lower in the positive control group and H-GOO ( Figure 6 D).

[0080] 2-7. IPITT results

[0081] According to Table 6, blood glucose after 6 hours of fasting showed a similar pattern to fasting blood glucose.

[0082] In the insulin tolerance test to determine insulin resistance, when 1U / kg bw of insulin was injected intraperitoneally into mice fasting for 6 hours, the positive control group had the lowest blood glucose change, while H-GOO was similar to the positive control group. Compared with the control group, insulin resistance was significantly improved ( Figure 7 A).

[0083] When insulin was injected intraperitoneally at 1 U / kg bw, the blood glucose of the positive control group was the lowest compared with other groups at 15 minutes, and continued to decrease until 30 minutes, and then maintained the blood glucose level, and rebounded after 75 minutes.

[0084] After insulin injection, the blood glucose area was the highest in the control group during 0-40 minutes, and was lower in the positive control group and H-GOO. At 40-90 minutes, the positive control group and the control group were very low compared with the control group, and decreased in a dose-dependent manner in GOO ( Figure 7 B).

[0085] 2-8. Lipid metabolism and liver function indicators

[0086] Table 7 shows the lipid profile and liver injury index after 4 weeks of intervention. Compared with the control group, the serum total cholesterol concentration and serum LDL concentration of the positive control group were lower, and decreased in a dose-dependent manner in GOO, and H-GOO was higher than the positive control group. On the contrary, the serum HDL concentration was higher in the positive control group compared with the control group, and increased in a dose-dependent manner in GOO, and H-GOO was lower than the positive control group. The serum neutral fat concentration also showed a value similar to the serum total cholesterol concentration, and H-GOO was lower than the positive control group. There was no difference in AST (liver function index) among the groups, but in terms of ALT activity, the positive control group was lower and the GOO intake group was lower compared with the control group (Table 7).

[0087] [Table 7]

[0088]

[0089] 2-9. Changes in leg length and bone density

[0090] When the difference in length at the end of the tibia and femur was calculated relative to the start, both leg bones were longer in the positive control group relative to the control group, and increased in a dose-dependent manner in GOO, and were the longest in H-GOO. In particular, in the tibia, when GOO was taken, it increased in a concentration-dependent manner, and it was considered to be the best in H-GOO. In addition, the length of the femur in the positive control group was also longer relative to the control group, and was longer in the group taking GOO than in the control group ( Figure 8 A).

[0091] Compared with the control group, the bone density of the lumbar spine and legs was higher in the positive control group. When GOO was taken, it increased in a concentration-dependent manner. In HGOO, the bone density of the lumbar spine and legs was higher than that of the control group and showed values ​​similar to those of the positive control group ( Figure 8 B).

[0092] The epiphyseal plate is divided into the proliferative zone, maturation zone, and hypertrophy zone. In both, the positive control group was higher than the control group, increased in a dose-dependent manner in GOO, and was even higher in the H-GOO group ( Fig. 9 C).

[0093] 2-10. Indicators involved in bone metabolism

[0094] The bone metabolism factors of mice fed with supplementary diets treated with scallion and oat extract (GOO) at low (L), medium (M), and high (H) doses are shown in Table 8 below. Relative to the control group, the serum growth hormone concentration was higher in the positive control group, and increased in a dose-dependent manner in GOO, and the H-GOO group was higher than the positive control group. There was no group difference in serum IGF-1 concentration. Relative to the control group, the serum osteocalcin concentration was higher in the positive control group, and GOO was as high as the positive control group at all doses. Relative to the control group, the serum osteoprotegerin concentration was higher in the positive control group, increased in a dose-dependent manner in GOO, and was higher in M-GOO and H-GOO. Relative to the control group, the serum bone-specific alkaline phosphatase (bone-specific ALP) activity was also higher in the positive control group, and increased in a dose-dependent manner in GOO, and was the highest in H-GOO (Table 8).

[0095] [Table 8]

[0096]

[0097] 2-11. Inflammation-related indicators

[0098] The serum TNF-a and IL-1b concentrations were the highest in the control group and the lowest in the positive control group. The serum TNF-a in H-GOO showed a value similar to that in the positive control group, and IL-1b in GOO showed a value similar to that in the positive control group regardless of the dose (Table 8).

[0099] 2-12. Changes in intestinal microbial flora and short-chain lipids Fatty acid (sh ortchainfattyacids) concentration

[0100] Compared with the control group, the Chaol and Shannon indices (α-diversity indices representing the diversity of intestinal microbial flora) were higher in the positive control group and increased in a concentration-dependent manner in GOO ( Fig.10 A).

[0101] The beta diversity, which indicates changes in intestinal microorganisms in different groups, also differed between the groups. The difference between the control group and the positive control group was large, and M-GOO and H-GOO were different from the control group ( Fig.10 B).

[0102] From the perspective of the phylum level and genus level of intestinal microorganisms, the positive control group had a higher Verrmcomicrobiota and a decreasing trend of Actinobacteria. In GOO, Actinobacteria decreased and Verrmcomicrobiota increased ( Fig.11 C).

[0103] At the genus level, compared with the control group, the positive control group had higher Blautia and Akkermentia, and lower Lactobacillus, Romboutsia, and Escherichia, and in GOO, Lactobacillus and Akkermentia increased, and Olsenella decreased.

[0104] In metagenome function, there was no significant difference in viral infection-related pathways between the control group and the positive control group, but GOO has the function of inhibiting virus-related infections, so it may contribute to height growth by reducing the adverse effects of infection on health.

[0105] The other axis is the neurotransmitter system and steroid biosynthesis. In the neurotransmitter system, the metabolism of serotonergic synapse and dopaminergic synapse in the positive control group showed a downward trend compared with the control group, while it was lower in GOO than in the control group, indicating that GOO inhibits the decomposition of components corresponding to the neurotransmitter system.

[0106] In contrast, the biosynthesis of steroids, sequiterpenoids, and triterpenoids in the control group was lower than that in the positive control group, and the biosynthesis mechanism of GOO was further enhanced compared with the positive control group.

[0107] 2-13. Effects of oat extract and barley extract on osteoblasts in MG63 cells The impact of growth

[0108] MG63 cells were treated with 1μg / mL, 5μg / mL, and 20μg / mL of oat extract and barley extract, and then treated with 100μg / mL of palmitate 1 hour later to test whether oat extract and barley extract inhibit palmitate-based cytotoxicity and improve cell growth. The results showed that oat extract and barley extract inhibited palmitate-based cytotoxicity and inhibited cell apoptosis in a concentration-dependent manner, thereby improving cell survival rate ( Fig.13 ).

[0109] 2-14. Conclusion

[0110] Scallion and oat extracts increase height growth in a dose-dependent manner and show that they increase epiphyseal plate growth as well as the positive control group administered with growth hormone. The mechanism is: increasing growth hormone secretion and increasing multiple indicators involved in bone growth (osteocalcin (OPG) and bone-specific alkaline phosphatase activity), thereby increasing bone density and bone length. Most of this increase is dose-dependent and effective at medium and high doses. Therefore, when mice ingest 200-500 mg / kg bw and children ingest 30-70 mg / kg bw, it is judged to be effective for height growth.

[0111] [Preparation Example 1. Pharmaceutical Preparation]

[0112] Preparation Example 1-1. Preparation of tablets

[0113] 200 mg of the scallion and oat extract of the present invention was mixed with 175.9 g of lactose, 180 g of potato starch and 32 g of colloidal silicic acid. After adding 10% gelatin solution to the mixture, it was crushed and passed through a 14-mesh sieve. It was dried and the mixture was made into tablets by adding 160 g of potato starch, 50 g of active ingredients and 5 g of magnesium stearate.

[0114] [Preparation Example 2. Preparation of health functional food]

[0115] Preparation Example 2-1. Preparation of health functional food

[0116] 1g of the scallion and oat extract of the present invention, an appropriate amount of vitamin mixture, 70μg of vitamin A acetate, 1.0mg of vitamin E, 0.13mg of vitamin B1, 0.15mg of vitamin B2, 0.5mg of vitamin B6, 0.2μg of vitamin B12, 10mg of vitamin C, 10μg of biotin, 1.7mg of nicotinamide, 50μg of folic acid, 0.5mg of calcium pantothenate, an appropriate amount of inorganic mixture, 1.75mg of ferrous sulfate, 0.82mg of zinc oxide, 25.3mg of magnesium carbonate, 15mg of potassium dihydrogen phosphate, 55mg of calcium hydrogen phosphate, 90mg of potassium citrate, 100mg of calcium carbonate, 24.8mg of magnesium chloride are mixed and prepared into granules, but can be deformed and prepared into various dosage forms according to the purpose. In addition, of course, the composition ratio of the vitamin and mineral mixture can be arbitrarily changed, and the ingredients can be mixed and prepared according to the preparation method of conventional health functional foods.

[0117] Preparation Example 2-2. Preparation of health functional beverage

[0118] 1g of the scallion and oat extract of the present invention, 0.1g of citric acid, 100g of oligofructose and 900g of purified water were mixed, and a beverage was prepared by stirring, heating, filtering, sterilizing and refrigerating according to a conventional beverage preparation method.

Claims

1. A pharmaceutical composition for increasing bone density or increasing bone length, comprising green onion and oat extract as active ingredients.

2. The pharmaceutical composition for increasing bone density or increasing bone length according to claim 1, characterized in that: The scallion and oat extracts are extracts based on any one solvent selected from the group consisting of water, alcohols with 1 to 4 carbon atoms, and mixtures thereof.

3. The pharmaceutical composition for increasing bone density or increasing bone length according to claim 1, characterized in that: The scallion and oat extracts are hot water extracts at a temperature of 70° C. to 90° C.

4. The pharmaceutical composition for increasing bone density or increasing bone length according to claim 1, characterized in that: The scallion white and oat extract is an extract obtained by mixing scallion white extract and oat extract in a weight ratio of 1:8-12.

5. The pharmaceutical composition for increasing bone density or increasing bone length according to claim 1, characterized in that: The pharmaceutical composition for increasing bone density or increasing bone length is used to increase the bone density or bone length of growing children or adolescents.

6. A health functional food composition for increasing bone density or increasing bone length, comprising green onion and oat extract as effective ingredients.

7. The health functional food composition for increasing bone density or increasing bone length according to claim 6, characterized in that: The scallion and oat extracts are extracts based on any one solvent selected from the group consisting of water, alcohols with 1 to 4 carbon atoms, and mixtures thereof.

8. The health functional food composition for increasing bone density or increasing bone length according to claim 6, characterized in that: The scallion and oat extracts are hot water extracts at a temperature of 70° C. to 90° C.

9. The health functional food composition for increasing bone density or increasing bone length according to claim 6, characterized in that: The scallion white and oat extract is an extract obtained by mixing scallion white extract and oat extract in a weight ratio of 1:8-12.

10. The health functional food composition for increasing bone density or increasing bone length according to claim 6, characterized in that: The health functional food composition for increasing bone density or increasing bone length is used for increasing the bone density or bone length of growing children or adolescents.

Citation Information

Patent Citations

  • COMPOSITION FOR BONE GROWTH PROMOTING COMPRISING Allium fistulosum L. AS AN ACTIVE INGREDIENT

    KR102070312B1

  • Electronic apparatus and method for obtaining capture image thereof

    KR1020240070298A

  • Instrument for the coagulation and dissection of biological tissue and method for operating such an instrument

    KR102766035B1